Tuesday, November 17, 2026
Harbor Dispatch

News, read across sources

Home / Society

Society

TB deaths are down 35% since 2015, but WHO says the first milestone arrived five years late

WHO's 2026 tuberculosis report counts 10.6 million cases and 1.1 million deaths in 2025. Domestic funding is rising, but the Americas are moving the wrong way.

4 min read

Photo: Janice Carr / CDC, public domain, via Wikimedia Commons / Wikimedia Commons, Public domain

Tuberculosis killed about 1.13 million people in 2025, 35% fewer than in 2015, and the world has now hit the first mortality target of the End TB Strategy. It did so five years after the date the strategy set. That is the headline of the World Health Organization’s Global Tuberculosis Report 2026, released on 12 November, and it is both a real achievement and a measure of how far behind schedule the response is.

The numbers behind the headline

According to WHO’s release, an estimated 10.6 million people developed TB in 2025 and 1.1 million died. The report’s own count of deaths is 1.13 million, down from 1.18 million in 2024, as Health Policy Watch reports. TB remains the leading cause of death from a single infectious agent. WHO estimates that treatment has saved about 86 million lives since 2000.

Deaths have fallen faster than new cases. Incidence is down 14% since 2015, against a milestone of a 50% cut by 2025. In 2025 there were 129 new cases per 100,000 people, 1.6% fewer than the year before.

One region going the other way

The global average hides a wide spread. WHO gives the change in incidence between 2015 and 2025 by region:

  • European Region: down 42%
  • African Region: down 30%
  • South-East Asia: down 18%
  • Eastern Mediterranean: down 6.6%
  • Western Pacific: no net change
  • The Americas: up 13%, and rising for a fifth consecutive year in 2025

WHO attributes the differences to risk factors, the strength of health systems, access to services and sustained investment. The burden is also concentrated: 30 countries account for 88% of people who developed TB in 2025. Health Policy Watch lists India at about a quarter of the global total, followed by Indonesia (10%), the Philippines (6.8%), China (6.5%) and Pakistan (6.4%), with eight countries making up about two-thirds.

Money, and who is paying

The funding picture is more mixed than the headline suggests. Domestic TB funding rose 14% to US$5.6 billion between 2024 and 2025, which WHO says partly offset a decline in international financing of a similar scale. The largest domestic increases came in India and Indonesia, according to Health Policy Watch.

Overall, the reporting from that outlet puts funding for TB prevention, diagnosis and treatment at US$6.6 billion, about 30% of the US$22 billion annual target for 2027, a gap WHO’s Tereza Kasaeva highlighted. Research is worse off: US$1.2 billion in 2023, less than a quarter of the US$5 billion annual target.

The honest reading of the 2025 data is that funding cuts have not yet shown up clearly. Katherine Floyd, who leads monitoring and evaluation at WHO, said there was “no clear-cut negative impact on TB diagnosis, treatment and prevention in 2025,” and added that “impacts may be delayed.” Most indicators moved slowly in the right direction or stayed stable between 2024 and 2025.

Who is still missed

The 2025 report numbers show where services fall short.

  • Of the 10.6 million people who developed TB, 8.4 million were diagnosed. About 2.2 million were undiagnosed or not reported.
  • Only 59% of newly diagnosed patients were tested with a WHO-recommended rapid test. The target for 2027 is 100%.
  • About 370,000 people developed rifampicin-resistant TB, a form that does not respond to a key first-line drug. Only 42% of them received treatment.
  • Among those treated for drug-resistant TB, uptake of the WHO-recommended six-month regimen rose from 18% in 2024 to 42% in 2025.

What comes next

WHO’s calls are familiar: strengthen political commitment, protect and increase financing, expand prevention and rapid diagnosis, and accelerate new vaccines, diagnostics and treatments. WHO’s Director-General, Tedros Adhanom Ghebreyesus, noted that “more than one million people still die each year” from a disease that is preventable and treatable.

The research community sounds more upbeat. Charlie Weller, Head of Vaccines at Wellcome, called this “a really exciting moment in TB innovation,” with improved treatments moving toward late-stage trials and several vaccines being tested. Wellcome argues that financing and delivery plans should be set up now so that, if trials succeed, equitable access in the countries with the greatest need does not wait years.

The next report will show whether the cuts in international funding arrive in the data. For now the world is cutting deaths at a pace it could sustain only if the money holds, and the 2030 targets look distant.

Sources

  1. WHO: Amid challenges, countries increase domestic investment to protect progress against tuberculosis (12 November 2026) who.int
  2. Health Policy Watch: Global Tuberculosis Burden Declining, but Five Years Behind Schedule healthpolicy-watch.news
  3. Wellcome: Wellcome responds to the WHO Global TB Report 2026 wellcome.org